Despite evidence that interleukin (IL) 23 works as a precursor to Th17 cells, the T lymphocytes that produce IL-17, and even though IL-23 inhibition exhibits substantial efficacy in the treatment of psoriasis, blocking IL-23 did not demonstrate any clinical efficacy in the treatment of axial spondyloarthritis [7]. The gene discussed is IL37; the disease is psoriasis.